文献速递新发突发、热带与寄生虫病

RTS,S/AS01E疫苗 efficacy 仅在基线有疟原虫血症的肯尼亚成人中显现

Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan Adults.
PubMed 文献 · J Infect Dis · 2025-01-01

一项在肯尼亚成人中开展的2b期研究显示,RTS,S/AS01E疫苗对基线存在恶性疟原虫感染且经抗疟药治疗者的疫苗效力为34.8%(95%CI 8.9%至53.4%),而对基线无疟原虫血症者为-24.0%(95%CI -97%至22.4%)。抗环子孢子蛋白抗体滴度在基线感染状态、药物治疗及感染易感性间无统计学差异,接种期间治疗疟原虫感染未提高疫苗效力。

要点

  • 基线疟原虫阳性者疫苗效力34.8%,阴性者为-24.0%。
  • 抗CS抗体滴度不因基线感染状态或药物治疗而改变。
  • 接种期间治疗疟原虫感染未提高疫苗效力。

核心结论

  • 接种期间治疗恶性疟原虫感染未导致疫苗效力提高。
  • 抗CS抗体应答不因基线感染状态、药物治疗或感染易感性而不同。

研究设计与样本

  • 在肯尼亚成人中开展的2b期研究,评估RTS,S/AS01E联合抗疟化学预防药物的效力。
  • 参与者按基线有无恶性疟原虫感染分组,随机接受RTS,S/AS01E或狂犬病疫苗。
  • 四组在免疫前接受抗疟药并随访6个月评估恶性疟原虫感染,另设一组未接受抗疟药用于免疫学评估。

主要发现

  • 疫苗效力(RTS,S/AS01E vs 狂犬病疫苗)在基线疟原虫阳性者为34.8%(95%CI 8.9%至53.4%),在基线疟原虫阴性者为-24.0%(95%CI -97%至22.4%)。
  • 在RTS,S/AS01E受者中,基线疟原虫阳性与阴性者的抗CS抗体滴度无统计学差异。
  • 在RTS,S/AS01E受者中,基线疟原虫阳性与阴性者在接种后随访期间对感染的易感性无统计学差异。
  • 药物治疗未改善抗CS抗体滴度。

关键数值与推荐

  • 疫苗效力(RTS,S/AS01E vs 狂犬病疫苗)基线疟原虫阳性者34.8%(95%CI 8.9%至53.4%)。
  • 疫苗效力(RTS,S/AS01E vs 狂犬病疫苗)基线疟原虫阴性者-24.0%(95%CI -97%至22.4%)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RTS,S/AS01 vaccine efficacy (VE) was previously shown as lower in African adults than in malaria-naive US adults, potentially due to concurrent Plasmodium falciparum infections. We investigated whether treatment of infection prior to vaccination would lead to improved VE and immunogenicity. METHODS: A phase 2b study in Kenyan adults evaluated the efficacy of RTS,S/AS01E in conjunction with antimalarial chemopreventive drugs. Participants, grouped by baseline presence or absence of P. falciparum infections, were randomized to receive RTS,S/AS01E or rabies vaccine. Four groups received antimalarial drugs prior to immunization and were followed for 6 months to assess P. falciparum infection. We included an additional group not treated with antimalarial drugs for immunological assessment. RESULTS: VE (RTS,S/AS01E vs rabies vaccine) was 34.8% (95% confidence interval [CI], 8.9% to 53.4%) and -24.0% (95% CI, -97% to 22.4%) in baseline P. falciparum-positive and P. falciparum-negative participants, respectively. In RTS,S/AS01E recipients, there were no statistical differences in anticircumsporozoite (anti-CS) antibody titers in baseline P. falciparum-positive or P. falciparum-negative participants, or in susceptibility to infection during the postvaccination follow-up period. Drug treatment did not improve anti-CS antibody titers. CONCLUSIONS: Treating P. falciparum infections during vaccination does not result in increased VE. Anti-CS antibody responses to vaccination do not differ with baseline P. falciparum infection status, drug treatment, or susceptibility to P. falciparum infections. CLINICAL TRIALS REGISTRATION: NCT04661579; PACTR202006896481432.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Copeland NK, Otieno L, Otieno JD, et al. Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan Adults. J Infect Dis. 2025. PMID: 40439411. doi:10.1093/infdis/jiaf274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。